Hepatitis C virus infection and risk of liver-related and non-liver-related deaths: a population-based cohort study in Naples, southern Italy

Abstract

Background Hepatitis C virus (HCV) infection represents a global health issue with severe implications on morbidity and mortality. This study aimed to evaluate the impact of HCV infection on all-cause, liver-related, and non-liver-related mortality in a population living in an area with a high prevalence of HCV infection before the advent of Direct-Acting Antiviral (DAA) therapies, and to identify factors associated with cause-specific mortality among HCV-infected individuals. Methods We conducted a cohort study on 4492 individuals enrolled between 2003 and 2006 in a population-based seroprevalence survey on viral hepatitis infections in the province of Naples, southern Italy. Study participants provided serum for antibodies to HCV (anti-HCV) and HCV RNA testing. Information on vital status to December 2017 and cause of death were retrieved through record-linkage with the mortality database. Hazard ratios (HRs) for cause-specific mortality and 95% confidence intervals (CIs) were estimated using Fine-Grey regression models. Results Out of 626 deceased people, 20 (3.2%) died from non-natural causes, 56 (8.9%) from liver-related conditions, 550 (87.9%) from non-liver-related causes. Anti-HCV positive people were at higher risk of death from all causes (HR = 1.38, 95% CI: 1.12–1.70) and liver-related causes (HR = 5.90, 95% CI: 3.00–11.59) than anti-HCV negative ones. Individuals with chronic HCV infection reported an elevated risk of death due to liver-related conditions (HR = 6.61, 95% CI: 3.29–13.27) and to any cause (HR = 1.51, 95% CI: 1.18–1.94). The death risk of anti-HCV seropositive people with negative HCV RNA was similar to that of anti-HCV seronegative ones. Among anti-HCV positive people, liver-related mortality was associated with a high FIB-4 index score (HR = 39.96, 95% CI: 4.73–337.54). Conclusions These findings show the detrimental impact of HCV infection on all-cause mortality and, particularly, liver-related mortality. This effect emerged among individuals with chronic infection while those with cleared infection had the same risk of uninfected ones. These results underline the need to identify through screening all people with chronic HCV infection notably in areas with a high prevalence of HCV infection, and promptly provide them with DAAs treatment to achieve progressive HCV elimination and reduce HCV-related mortality.

Intention to Screen for Hepatitis C Among University Students: Influence of Different Communicative Scenarios

“…If we consider the data relating to direct knowledge of at least one infected with hepatitis C, 14.7%, added to the 5.5% of those who declared they knew two or more infected with hepatitis C, it clearly emerges that the infection in question is by no means a marginal occurrence in the current Italian framework, as confirmed by official statistics ( 7 , 58 ).…”

Hijacking autophagy for infection by flaviviruses

“…Hepatitis C virus (HCV), which is transmitted through the bloodstream, is one of the leading causes of chronic liver diseases. Hepatocellular carcinoma is a major complication associated with HCV infection, with significant morbidity and mortality rates ( Piselli et al, 2021 ). HCV evades innate and adaptive immunity and develops chronic infection in 70% of cases, posing a major health burden worldwide.…”

Liver Fibrosis in Individuals With Hepatitis C Virus Genotype 1B From Brazilian Eastern Amazon

“…Complications will be developed by 55 -85% of infected people. Liver Cirrhosis and hepatocellular carcinoma were responsible for approximately 290,000 deaths associated with the disease in the year of 2019 2,3,4 . Chronic HCV is one of the main health problems globally, with highest rate of complications in comparison to other viral hepatitis.…”